GET DAILY SIGNALSAutolus Therapeutics (AUTL): Analyst Targets Point to +465% Upside Potential
Key Takeaways
- The central $8.75 price target is the arithmetic mean of roughly nine current analyst price targets (underlying average of about $8.73), reflecting a "Strong Buy" consensus.
- With shares around $1.55, reaching $8.75 would require a gain of roughly 465%, a very large move by any standard.
- Individual targets range from about $5 to $11, an unusually wide spread that signals deep disagreement about the company's path to profitability.
- The strongest support is the commercial ramp of AUCATZYL, a CAR-T therapy for B-cell acute lymphoblastic leukemia (ALL), plus a growing autoimmune and neurology pipeline.
- The biggest risks are persistent net losses, a limited cash runway into late 2027, and an intensely competitive cell-therapy market.
- No sell-rated or hold-rated targets were found; every firm cited maintains a Buy or equivalent rating, though the low end of the range remains far above the current price.
- For more on this ticker, explore Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- Readers can also explore Trending AI Robots for automated market monitoring tools.
Analyst Price Targets and Consensus View
Autolus Therapeutics plc (AUTL) is a UK-based, commercial-stage biopharmaceutical company developing programmed T-cell (CAR-T) therapies for cancer and autoimmune diseases. Roughly nine current sell-side price targets were reviewed for this analysis, spanning approximately $5 to $11. The arithmetic mean is about $8.73, which rounds to a central target of $8.75.
The targets cluster in two groups. Needham, H.C. Wainwright, and Mizuho all publish $10 targets, while Goldman Sachs carries a $5.80 target (raised from $5.40 in August 2026) and Wells Fargo holds the low end at $5. William Blair reiterates a Buy rating but does not publish a dollar target. Needham, which named AUTL a top pick for 2026, argues the shares are attractively valued and models breakeven by 2028 on AUCATZYL sales alone. The cautious end of the range reflects skepticism about whether commercialization can outpace heavy spending. This wide dispersion is not unusual for an early-stage commercial biotech, but it means the "average analyst price target" should be read as a midpoint of divergent scenarios rather than a precise forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares closed near $1.55 in late October 2026, toward the lower portion of a 52-week range of roughly $1.18 to $2.58. The company carries a market capitalization of approximately $413 million with trailing 12-month revenue of about $117 million and a net loss of roughly $280 million. Because the stock has no meaningful earnings, it trades on revenue multiples and pipeline expectations rather than a price-to-earnings ratio.
From $1.55, the move to $8.75 represents upside of approximately 465%, which must be characterized as very large. A path to that level would likely require several things to go right at once: continued acceleration of AUCATZYL revenue, successful early data readouts in lupus nephritis and multiple sclerosis, and a credible timeline to breakeven that persuades investors the company will not need heavily dilutive financing.
What Could Support a Move Toward the Target
Autolus has meaningfully improved its commercial trajectory. AUCATZYL generated $45.7 million in net product revenue in the second quarter of 2026, up from $20.9 million a year earlier, and management raised full-year 2026 guidance to $140–150 million from $120–135 million. The company also secured a credit facility of up to $250 million with Perceptive Advisors, with $75 million funded at close, and expects its cash to fund operations into the fourth quarter of 2027.
Beyond the approved indication, the pipeline is the main source of upside. Obe-cel is being studied in lupus nephritis, progressive multiple sclerosis, light-chain amyloidosis, and pediatric B-ALL, and the FDA granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel. Analysts modeling the stock's potential value creation point to these optionalities, which receive little credit at the current share price. From what I see, this pipeline optionality deserves closer attention.
What Could Prevent the Target From Being Reached
The obstacles are substantial. The company remains deeply unprofitable, with a trailing net loss of roughly $280 million and negative earnings per share of about $1.05. Even with narrowing losses forecast for 2026, the business is expected to stay loss-making for the next several years. A 13% workforce reduction announced in 2026 underscores the pressure to control costs.
Competition in CD19-directed CAR-T and broader cell therapy is intense, and institutional ownership declined in recent quarters. The stock also trades below its book value, a sign the market is not yet convinced the commercial business can generate durable returns. Any clinical setback, slower-than-expected treatment-center uptake, or additional share issuance to raise capital could keep the shares depressed and the target well out of reach.
Technical Levels and Market Structure
Technically, the shares sit well below all analyst price targets, with meaningful resistance near the $2.00 round level and the 52-week high around $2.58. Support is visible near $1.50 and again at the 52-week low around $1.18. A sustained move above $2.58 would represent a breakout from a prolonged downtrend and is a prerequisite for any credible advance toward the $5 to $10 levels implied by the analyst range.
Time Horizon and What Investors Should Monitor
Analyst price targets for AUTL generally reflect a roughly 12-month research horizon, though the spread between a $5 and an $11 target shows analysts disagree sharply on how quickly value will emerge. The next key event is the third-quarter earnings report scheduled for November 10, 2026, which will update AUCATZYL revenue momentum and cash position. Investors should also watch initial data from the progressive MS and amyloidosis programs expected by year-end 2026, any guidance revisions, and analyst target changes following earnings. I’m watching this closely for any shifts in momentum.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders spot opportunities, track existing positions, and identify shifting trends more efficiently than manual screening. For a volatile, event-driven name like Autolus, where clinical catalysts can move the stock sharply, such tools can complement fundamental research by surfacing real-time changes in momentum. In my view, integrating these signals has helped refine my timing on names with binary events ahead.
Final Assessment
The $8.75 central target, derived from the average of roughly nine analyst price targets spanning about $5 to $11, implies a gain of approximately 465% from the current price near $1.55 — a very large move that would require flawless commercial execution and positive clinical data across multiple programs. The bull case rests on accelerating AUCATZYL sales and a pipeline that analysts argue is undervalued, while the bear case centers on sustained losses, a constrained cash runway, and fierce competition. With every covering firm maintaining a Buy rating but targets diverging dramatically, the target represents an aspirational scenario rather than a base case, and no outcome should be treated as assured.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AUTL in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 13, 2026
AUTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where AUTL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AUTL's RSI Indicator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUTL advanced for three days, in 223 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AUTL as a result. In 58 of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
AUTL moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AUTL crossed bearishly below the 50-day moving average on September 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for AUTL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. AUTL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.513) is normal, around the industry mean (2.974). P/E Ratio (-1.462) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of cancer treatments
Industry Biotechnology
Advertisement